
EmmaCare is an innovative Clinical Care Management virtual assistant platform that enhances patient engagement and reduces care management costs by leveraging AI technology and gamification. It supports chronic care management, annual wellness visits, behavioral health integration, and transitional care management. The platform improves care efficiency by managing larger patient census, increasing patient touch points, improving patient satisfaction, and closing care gaps through features like clinical pathways, real-time monitoring, medication management, and patient education. EmmaCare integrates seamlessly with EMRs and medical devices, providing care managers with dashboards to manage alerts, communicate with patients, and analyze trends, positioning it as a scalable solution in healthcare management.

EmmaCare is an innovative Clinical Care Management virtual assistant platform that enhances patient engagement and reduces care management costs by leveraging AI technology and gamification. It supports chronic care management, annual wellness visits, behavioral health integration, and transitional care management. The platform improves care efficiency by managing larger patient census, increasing patient touch points, improving patient satisfaction, and closing care gaps through features like clinical pathways, real-time monitoring, medication management, and patient education. EmmaCare integrates seamlessly with EMRs and medical devices, providing care managers with dashboards to manage alerts, communicate with patients, and analyze trends, positioning it as a scalable solution in healthcare management.
What they do: AI-enabled clinical care management virtual assistant for patient engagement and care program automation
Founded / HQ: 2019 · New York, NY
Team size (reported): ~7 employees
Disclosed funding: Seed round (announced 2022-03-16); reported total funding $3,000,000
Clinical care management and patient engagement across chronic and transitional care programs
2019
Healthtech
Seed round announced on 2022-03-16; investor names not disclosed in provided evidence.